CTOR Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Citius Oncology's net margin of -49.65%. Citius Oncology's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 384.57%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 73.47%. Given that Citius Oncology has higher upside potential than NovaBay Pharmaceuticals, analysts believe Citius Oncology is more attractive than NovaBay Pharmaceuticals.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Citius Oncology's net income of -$6.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Citius Oncology's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus 0.13x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Predictive Oncology has a net margin of -- compared to Citius Oncology's net margin of -895.23%. Citius Oncology's return on equity of -- beat Predictive Oncology's return on equity of -232.54%.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 384.57%. On the other hand Predictive Oncology has an analysts' consensus of -- which suggests that it could grow by 208.17%. Given that Citius Oncology has higher upside potential than Predictive Oncology, analysts believe Citius Oncology is more attractive than Predictive Oncology.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Predictive Oncology has a beta of 1.111, suggesting its more volatile than the S&P 500 by 11.127%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Predictive Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. Predictive Oncology pays out -- of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than Predictive Oncology quarterly revenues of $345.7K. Citius Oncology's net income of -$6.7M is lower than Predictive Oncology's net income of -$3.1M. Notably, Citius Oncology's price-to-earnings ratio is -- while Predictive Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus 3.20x for Predictive Oncology. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Citius Oncology's net margin of -2357.27%. Citius Oncology's return on equity of -- beat Palatin Technologies's return on equity of --.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 384.57%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Citius Oncology, analysts believe Palatin Technologies is more attractive than Citius Oncology.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Citius Oncology's net income of -$6.7M is lower than Palatin Technologies's net income of -$2.4M. Notably, Citius Oncology's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Citius Oncology's net margin of --. Citius Oncology's return on equity of -- beat Theriva Biologics's return on equity of --.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 384.57%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 412.82%. Given that Theriva Biologics has higher upside potential than Citius Oncology, analysts believe Theriva Biologics is more attractive than Citius Oncology.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Citius Oncology's net income of -$6.7M is lower than Theriva Biologics's net income of -$4.4M. Notably, Citius Oncology's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.